Treatment of primary systemic vasculitis with the inosine monophosphate dehydrogenase inhibitor mycophenolic acid

Nephron - Clinical Practice

Volumn 116, Issue 1, 2010, Pages

  Hiemstra, Thomas F ^a,b   Jones, Rachel B ^a   Jayne, David R W ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Antineutrophil cytoplasmic antibody; Mycophenolate mofetil; Mycophenolic acid; Toxicity; Vasculitis

Indexed keywords

CYCLOPHOSPHAMIDE; GLUCOCORTICOID; INOSINATE DEHYDROGENASE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEUTROPHIL CYTOPLASMIC ANTIBODY;

AORTA ARCH SYNDROME; AREA UNDER THE CURVE; AUTOIMMUNE DISEASE; BEHCET DISEASE; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG MONITORING; GIANT CELL ARTERITIS; HUMAN; KIDNEY DYSFUNCTION; KIDNEY FIBROSIS; LACTATION; PREGNANCY; PRIORITY JOURNAL; REMISSION; SHORT SURVEY; SYSTEMIC VASCULITIS;

ANIMALS; ENZYME INHIBITORS; HUMANS; IMP DEHYDROGENASE; MYCOPHENOLIC ACID; PRODRUGS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SIGNAL TRANSDUCTION; SYSTEMIC VASCULITIS; TREATMENT OUTCOME;

EID: 77952316607     PISSN: 16602110     EISSN: None     Source Type: Journal    
DOI: 10.1159/000314543     Document Type: Short Survey

References (81)

1. Walton EW: Giant-cell granuloma of the respiratory tract (Wegener's granulomatosis). Br Med J 1958;ii:265-270.
2. Hiemstra TF, Jayne D: Newer therapies for vasculitis. Best Pract Res Clin Rheumatol 2009; 23: 379-389.
3. Pagnoux C, Mahr A, Hamidou MA, Boffa JJ, Ruivard M, Ducroix JP, Kyndt X, Lifermann F, Papo T, Lambert M, Le Noach J, Khellaf M, Merrien D, Puechal X, Vinzio S, Cohen P, Mouthon L, Cordier JF, Guillevin L: Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med 2008; 359: 2790-2803.
4. Booth AD, Almond MK, Burns A, Ellis P, Gaskin G, Neild GH, Plaisance M, Pusey CD, Jayne DR: Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. Am J Kidney Dis 2003; 41: 776-784.
5. Bosch X, Guilabert A, Espinosa G, Mirapeix E: Treatment of antineutrophil cytoplasmic antibody associated vasculitis: a systematic review. JAMA 2007; 298: 655-669.
6. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group. Lancet 1995; 345: 1321-1325.
7. Ekberg H, Bernasconi C, Tedesco-Silva H, Vitko S, Hugo C, Demirbas A, Acevedo RR, Grinyo J, Frei U, Vanrenterghem Y, Daloze P, Halloran P: Calcineurin inhibitor minimization in the symphony study: observational results 3 years after transplantation. Am J Transplant 2009; 9: 1876-1885.
8. Karim MY, Alba P, Cuadrado MJ, Abbs IC, D'Cruz DP, Khamashta MA, Hughes GR: Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents. Rheumatology (Oxford) 2002; 41: 876-882.
9. Fickert P, Hinterleitner TA, Wenzl HH, Aichbichler BW, Petritsch W: Mycophenolate mofetil in patients with Crohn's disease. Am J Gastroenterol 1998; 93: 2529-2532.
10. Sollinger HW: Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1995; 60: 225-232.
11. Lang P, Pardon A, Audard V: Long-term benefit of mycophenolate mofetil in renal transplantation. Transplantation 2005; 79:S47-S48.
12. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation 1996; 61: 1029-1037.
13. Meier-Kriesche HU, Steffen BJ, Hochberg AM, Gordon RD, Liebman MN, Morris JA, Kaplan B: Long-term use of mycophenolate mofetil is associated with a reduction in the incidence and risk of late rejection. Am J Transplant 2003; 3: 68-73.
14. Burke GW 3rd, Kaufman DB, Millis JM, Gaber AO, Johnson CP, Sutherland DE, Punch JD, Kahan BD, Schweitzer E, Langnas A, Perkins J, Scandling J, Concepcion W, Stegall MD, Schulak JA, Gores PF, Benedetti E, Danovitch G, Henning AK, Bartucci MR, Smith S, Fitzsimmons WE: Prospective, randomized trial of the effect of antibody induction in simultaneous pancreas and kidney transplantation: three-year results. Transplantation 2004; 77: 1269-1275.
15. Remuzzi G, Cravedi P, Costantini M, Lesti M, Ganeva M, Gherardi G, Ene-Iordache B, Gotti E, Donati D, Salvadori M, Sandrini S, Segoloni G, Federico S, Rigotti P, Sparacino V, Ruggenenti P: Mycophenolate mofetil versus azathioprine for prevention of chronic allograft dysfunction in renal transplantation: the MYSS follow-up randomized, controlled clinical trial. J Am Soc Nephrol 2007; 18: 1973-1985.
16. Kainz A, Heinze G, Korbely R, Schwarz C, Oberbauer R: Mycophenolate mofetil use is associated with prolonged graft survival after kidney transplantation. Transplantation 2009; 88: 1095-1100.
17. Houssiau FA, D'Cruz DP, Sangle SR, Remy P, Vasconcelos C, Garrido E, Gilboe Sr IM, Ravelingien I, Tektonidou M, Depresseux G, Guillevin LP, Cervera R: Azathioprine versus mycophenolate mofetil for maintenance immunosuppression of proliferative lupus nephritis: results of a randomized trial (MAINTAIN). ACR Abstract. Arthritis Rheum 2009; 60(suppl):1150.
18. Chan TM, Li FK, Tang CS, Wong RW, Fang GX, Ji YL, Lau CS, Wong AK, Tong MK, Chan KW, Lai KN: Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 2000; 343: 1156-1162.
19. Chan TM, Tse KC, Tang CS, Mok MY, Li FK: Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 2005; 16: 1076-1084.
20. Ong LM, Hooi LS, Lim TO, Goh BL, Ahmad G, Ghazalli R, Teo SM, Wong HS, Tan SY, Shaariah W, Tan CC, Morad Z: Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis. Nephrology (Carlton) 2005; 10: 504-510.
21. Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT, Petri M, Gilkeson GS, Wallace DJ, Weisman MH, Appel GB: Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005; 353: 2219-2228.
22. Flores-Suarez LF, Villa AR: Open randomized trial comparing mycophenolate mofetil versus intravenous cyclophosphamide as induction therapy for severe lupus nephritis. J Am Soc Nephrol 2004; 15:PO257.
23. Glicklich D, Acharya A: Mycophenolate mofetil therapy for lupus nephritis refractory to intravenous cyclophosphamide. Am J Kidney Dis 1998; 32: 318-322.
24. Briggs WA, Choi MJ, Scheel PJ Jr: Successful mycophenolate mofetil treatment of glomerular disease. Am J Kidney Dis 1998; 31: 213-217.
25. Walsh M, James M, Jayne D, Tonelli M, Manns BJ, Hemmelgarn BR: Mycophenolate mofetil for induction therapy of lupus nephritis: a systematic review and metaanalysis. Clin J Am Soc Nephrol 2007; 2: 968-975.
26. Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, Li LS, Mysler E, Sanchez-Guerrero J, Solomons N, Wofsy D: Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009; 20: 1103-1112.
27. Gozio B: Richerche bacteriologiche e chimiche sulle alterazoni del mais. Riv Igiene Sanita Pubbl Ann 1896; 7: 825.
28. Alsberg CL, Black OF: Contributions to the study of maize deterioration; biochemical and toxicological investigations of Penicillium puberulum and Penicillium stoloniferum. Bull US Bur Pl Ind 1913; 270: 7.
29. Sollinger HW, Deierhoi MH, Belzer FO, Diethelm AG, Kauffman RS: RS-61443 - a phase I clinical trial and pilot rescue study. Transplantation 1992; 53: 428-432.
30. Van Bruggen MC, Walgreen B, Rijke TP, Berden JH: Attenuation of murine lupus nephritis by mycophenolate mofetil. J Am Soc Nephrol 1998; 9: 1407-1415.
31. Heemann U, Azuma H, Hamar P, Schmid C, Tilney N, Philipp T: Mycophenolate mofetil inhibits lymphocyte binding and the upregulation of adhesion molecules in acute rejection of rat kidney allografts. Transplant Immunol 1996; 4: 64-67.
32. Lipsky JJ: Mycophenolate mofetil. Lancet 1996; 348: 1357-1359.
33. Bullingham RE, Nicholls AJ, Kamm BR: Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 1998; 34: 429-455.
34. Shipkova M, Armstrong VW, Wieland E, Niedmann PD, Schutz E, Brenner-Weiss G, Voihsel M, Braun F, Oellerich M: Identification of glucoside and carboxyl-linked glucuronide conjugates of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. Br J Pharmacol 1999; 126: 1075-1082.
35. Shipkova M, Armstrong VW, Weber L, Niedmann PD, Wieland E, Haley J, Tonshoff B, Oellerich M: Pharmacokinetics and protein adduct formation of the pharmacologically active acyl glucuronide metabolite of mycophenolic acid in pediatric renal transplant recipients. Ther Drug Monit 2002; 24: 390-399.
36. Gonzalez-Roncero FM, Govantes MA, Chaves VC, Palomo PP, Serra MB: Influence of renal insufficiency on pharmacokinetics of acyl-glucuronide metabolite of mycophenolic acid in renal transplant patients. Transplant Proc 2007; 39: 2176-2178.
37. Shipkova M, Wieland E, Schutz E, Wiese C, Niedmann PD, Oellerich M, Armstrong VW: The acyl glucuronide metabolite of mycophenolic acid inhibits the proliferation of human mononuclear leukocytes. Transplant Proc 2001; 33: 1080-1081.
38. Johnson HJ, Swan SK, Heim-Duthoy KL, Nicholls AJ, Tsina I, Tarnowski T: The pharmacokinetics of a single oral dose of mycophenolate mofetil in patients with varying degrees of renal function. Clin Pharmacol Ther 1998; 63: 512-518.
39. Naesens M, de Loor H, Vanrenterghem Y, Kuypers DR: The impact of renal allograft function on exposure and elimination of mycophenolic acid (MPA) and its metabolite MPA 7-O-glucuronide. Transplantation 2007; 84: 362-373.
40. MacPhee IA, Spreafico S, Bewick M, Davis C, Eastwood JB, Johnston A, Lee T, Holt DW: Pharmacokinetics of mycophenolate mofetil in patients with end-stage renal failure. Kidney Int 2000; 57: 1164-1168.
41. Hanada K, Ogawa R, Son K, Sasaki Y, Kikkawa A, Ichihara S, Ogata H: Effects of indoxylsulfate on the in vitro hepatic metabolism of various compounds using human liver microsomes and hepatocytes. Nephron Physiol 2006; 103:p179-p186.
42. Sanchez Fructuoso AI, de la Higuera MA, Garcia-Ledesma P, Giorgi M, Ramos F, Calvo N, Perez-Flores I, Barrientos A: Graft outcome and mycophenolic acid trough level monitoring in kidney transplantation. Transplant Proc 2009; 41: 2102-2103.
43. Borrows R, Chusney G, Loucaidou M, James A, Lee J, Tromp JV, Owen J, Cairns T, Griffith M, Hakim N, McLean A, Palmer A, Papalois V, Taube D: Mycophenolic acid 12-h trough level monitoring in renal transplantation: association with acute rejection and toxicity. Am J Transplant 2006; 6: 121-128.
44. Le Meur Y, Buchler M, Thierry A, Caillard S, Villemain F, Lavaud S, Etienne I, Westeel PF, Hurault de Ligny B, Rostaing L, Thervet E, Szelag JC, Rerolle JP, Rousseau A, Touchard G, Marquet P: Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am J Transplant 2007; 7: 2496-2503.
45. van Gelder T, Silva HT, de Fijter JW, Budde K, Kuypers D, Tyden G, Lohmus A, Sommerer C, Hartmann A, Le Meur Y, Oellerich M, Holt DW, Tonshoff B, Keown P, Campbell S, Mamelok RD: Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration- controlled trial. Transplantation 2008; 86: 1043-1051.
46. Jeong H, Kaplan B: Therapeutic monitoring of mycophenolate mofetil. Clin J Am Soc Nephrol 2007; 2: 184-191.
47. van Gelder T: Mycophenolate blood level monitoring: recent progress. Am J Transplant 2009; 9: 1495-1499.
48. Neumann I, Haidinger M, Jager H, Grutzmacher H, Griesmacher A, Muller MM, Bayer PM, Meisl FT: Pharmacokinetics of mycophenolate mofetil in patients with autoimmune diseases compared renal transplant recipients. J Am Soc Nephrol 2003; 14: 721-727.
49. Neumann I, Fuhrmann H, Fang IF, Jaeger A, Bayer P, Kovarik J: Association between mycophenolic acid 12-h trough levels and clinical endpoints in patients with autoimmune disease on mycophenolate mofetil. Nephrol Dial Transplant 2008; 23: 3514-3520.
50. Schaier M, Scharpf D, Scholl C, Hug F, Schwenger V, Zeier MG: Pharmacodynamic drug monitoring a new tool for individualised immunosuppression in patients with ANCA-associated systemic vasculitis. Am Soc Nephrol Abstracts. J Am Soc Nephrol 2009; 20(suppl):F-PO1300.
51. Hu W, Liu C, Xie H, Chen H, Liu Z, Li L: Mycophenolate mofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement. Nephrol Dial Transplant 2008; 23: 1307-1312.
52. de Groot K, Harper L, Jayne DR, Flores Suarez LF, Gregorini G, Gross WL, Luqmani R, Pusey CD, Rasmussen N, Sinico RA, Tesar V, Vanhille P, Westman K, Savage CO: Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 2009; 150: 670-680.
53. Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JW, Dadoniene J, Ekstrand A, Gaskin G, Gregorini G, de Groot K, Gross W, Hagen EC, Mirapeix E, Pettersson E, Siegert C, Sinico A, Tesar V, Westman K, Pusey C: A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003; 349: 36-44.
54. Stassen PM, Cohen Tervaert JW, Stegeman CA: Induction of remission in active antineutrophil cytoplasmic antibody-associated vasculitis with mycophenolate mofetil in patients who cannot be treated with cyclophosphamide. Ann Rheum Dis 2007; 66: 798-802.
55. Joy MS, Hogan SL, Jennette JC, Falk RJ, Nachman PH: A pilot study using mycophenolate mofetil in relapsing or resistant ANCA small vessel vasculitis. Nephrol Dial Transplant 2005; 20: 2725-2732.
56. Nowack R, Gobel U, Klooker P, Hergesell O, Andrassy K, Van der Woude F: Mycophenolate mofetil for maintenance therapy of Wegener's granulomatosis and microscopic polyangiitis: a pilot study in 11 patients with renal involvement. J Am Soc Nephrol 1999; 10: 1965-1971.
57. Kazderova M, Jancova E, Rysava R, Merta M, Tesar V: Mycophenolate mofetil in low doses stabilizes and improves antineutrophil cytoplasmic antibody-associated vasculitis and lupus nephritis. Arch Med Res 2008; 39: 115-119.
58. Koukoulaki M, Jayne DR: Mycophenolate mofetil in anti-neutrophil cytoplasm antibodies- associated systemic vasculitis. Nephron Clin Pract 2006; 102:c100-c107.
59. Langford CA, Talar-Williams C, Sneller MC: Mycophenolate mofetil for remission maintenance in the treatment of Wegener's granulomatosis. Arthritis Rheum 2004; 51: 278-283.
60. Assaf C, Mewis G, Orfanos CE, Geilen CC: Churg-Strauss syndrome: successful treatment with mycophenolate mofetil. Br J Dermatol 2004; 150: 598-600.
61. Hoffman GS, Ahmed AE: Surrogate markers of disease activity in patients with Takayasu arteritis. A preliminary report from the International Network for the Study of the Systemic Vasculitides (INSSYS). Int J Cardiol 1998; 66:S191-S194.
62. Kerr GS, Hallahan CW, Giordano J, Leavitt RY, Fauci AS, Rottem M, Hoffman GS: Takayasu arteritis. Ann Intern Med 1994; 120: 919-929.
63. Daina E, Schieppati A, Remuzzi G: Mycophenolate mofetil for the treatment of takayasu arteritis: report of three cases. Ann Intern Med 1999; 130: 422-426.
64. Shinjo SK, Pereira RM, Tizziani VA, Radu AS, Levy-Neto M: Mycophenolate mofetil reduces disease activity and steroid dosage in Takayasu arteritis. Clin Rheumatol 2007; 26: 1871-1875.
65. Worm M, Sterry W, Kolde G: Mycophenolate mofetil is effective for maintenance therapy of hypocomplementaemic urticarial vasculitis. Br J Dermatol 2000; 143: 1324.
66. Taverna JA, Radfar A, Pentland A, Poggioli G, Demierre MF: Case reports: nodular vasculitis responsive to mycophenolate mofetil. J Drugs Dermatol 2006; 5: 992-993.
67. Gladstone DE, Golightly MG, Zamkoff KW: Severe, refractory type ii essential mixed cryoglobulinemia treated with 2-chlorodeoxyadenosine and mycophenolate mofetil. Rheumatol Int 2005; 25: 635-636.
68. Adler YD, Mansmann U, Zouboulis CC: Mycophenolate mofetil is ineffective in the treatment of mucocutaneous Adamantiades- Behçet's disease. Dermatology 2001; 203: 322-324.
69. Ostensen M, Khamashta M, Lockshin M, Parke A, Brucato A, Carp H, Doria A, Rai R, Meroni P, Cetin I, Derksen R, Branch W, Motta M, Gordon C, Ruiz-Irastorza G, Spinillo A, Friedman D, Cimaz R, Czeizel A, Piette JC, Cervera R, Levy RA, Clementi M, De Carolis S, Petri M, Shoenfeld Y, Faden D, Valesini G, Tincani A: Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther 2006; 8: 209.
70. Sifontis NM, Coscia LA, Constantinescu S, Lavelanet AF, Moritz MJ, Armenti VT: Pregnancy outcomes in solid organ transplant recipients with exposure to mycophenolate mofetil or sirolimus. Transplantation 2006; 82: 1698-1702.
71. El Sebaaly Z, Charpentier B, Snanoudj R: Fetal malformations associated with mycophenolate mofetil for lupus nephritis. Nephrol Dial Transplant 2007; 22: 2722.
72. Schoner K, Steinhard J, Figiel J, Rehder H: Severe facial clefts in acrofacial dysostosis: a consequence of prenatal exposure to mycophenolate mofetil? Obstet Gynecol 2008; 111: 483-486.
73. Perez-Aytes A, Ledo A, Boso V, Saenz P, Roma E, Poveda JL, Vento M: In utero exposure to mycophenolate mofetil: a characteristic phenotype? Am J Med Genet 2008; 146A:1-7.
74. Jungraithmayr T, Staskewitz A, Kirste G, Boswald M, Bulla M, Burghard R, Dippell J, Greiner C, Helmchen U, Klare B, Klaus G, Leichter HE, Mihatsch MJ, Michalk DV, Misselwitz J, Plank C, Querfeld U, Weber LT, Wiesel M, Tonshoff B, Zimmerhackl LB: Pediatric renal transplantation with mycophenolate mofetil-based immunosuppression without induction: results after three years. Transplantation 2003; 75: 454-461.
75. Morath C, Schwenger V, Beimler J, Mehrabi A, Schmidt J, Zeier M, Muranyi W: Antifibrotic actions of mycophenolic acid. Clin Transplant 2006; 20(suppl 17):25-29.
76. Copeland JW, Beaumont BW, Merrilees MJ, Pilmore HL: Epithelial-to- mesenchymal transition of human proximal tubular epithelial cells: effects of rapamycin, mycophenolate, cyclosporin, azathioprine, and methylprednisolone. Transplantation 2007; 83: 809-814.
77. Nankivell BJ, Wavamunno MD, Borrows RJ, Vitalone M, Fung CL, Allen RD, Chapman JR, O'Connell PJ: Mycophenolate mofetil is associated with altered expression of chronic renal transplant histology. Am J Transplant 2007; 7: 366-376.
78. Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, de Groot K, Gross W, Hauser T, Hellmich B, Jayne D, Kallenberg CG, Merkel PA, Raspe H, Salvarani C, Scott DG, Stegeman C, Watts R, Westman K, Witter J, Yazici H, Luqmani R: EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 2009; 68: 310-317.
79. Stepkowski SM: Molecular targets for existing and novel immunosuppressive drugs. Expert Rev Mol Med 2000; 2: 1-23.
80. Yalcindag FN, Amer R, Forrester JV: Mycophenolate mofetil in the treatment of ocular inflammation in ANCA-associated vasculitis. J Ocul Pharmacol Ther 2008; 24: 249-254.
81. Iatrou C, Zerbala S, Revela I, Spanou E, Marinaki S, Nakopoulou L, Boletis J: Mycophenolate mofetil as maintenance therapy in patients with vasculitis and renal involvement. Clin Nephrol 2009; 72: 31-37.